

1 **Multilevel determinants of Covid-19 vaccine hesitancy and undervaccination among**
2 **marginalized populations in the United States: A scoping review**

3
4 Peter A. Newman^{1*}, Thabani Nyoni¹, Kate Allan¹, Sophia Fantus², Duy Dinh³, Suchon Tepjan⁴,
5 Luke Reid¹, Adrian Guta⁵

6
7 ¹ Factor-Inwentash Faculty of Social Work, University of Toronto, Toronto, Ontario, Canada

8 ² School of Social Work, University of Texas at Arlington, Texas, USA

9 ^{1,3} Faculty of Health Sciences, Queen's University, Kingston, Ontario, Canada

10 ^{1,4} VOICES-Thailand Foundation, Chiang Mai, Thailand

11 ⁵ School of Social Work, University of Windsor, Windsor, Ontario, Canada

12
13 ***Corresponding author**

14 E-mail: p.newman@utoronto.ca

15 **Abstract**

16 **Background:** Amid persistent disparities in Covid-19 vaccination, we conducted a scoping
17 review to identify multilevel determinants of Covid-19 vaccine hesitancy (VH) and
18 undervaccination among marginalized populations in the U.S.

19 **Methods:** We utilized the scoping review methodology developed by the Joanna Briggs Institute
20 and report all findings according to PRISMA-ScR guidelines. We developed a search string and
21 explored 7 databases to identify peer-reviewed articles published from January 1, 2020–October
22 31, 2021, the initial period of U.S. Covid-19 vaccine availability. We combine frequency
23 analysis and narrative synthesis to describe factors influencing Covid-19 vaccination among
24 marginalized populations.

25 **Results:** The search captured 2,496 non-duplicated records, which were scoped to 50 peer-
26 reviewed articles: 11 (22%) focused on African American/Black people, 9 (18%) people with
27 disabilities, 4 (8%) justice-involved people, and 2 (4%) each on Latinx, people living with
28 HIV/AIDS, people who use drugs, and LGBTQ+ people. Forty-four articles identified structural
29 factors, 36 social/community, 27 individual, and 40 vaccine-specific factors. Structural factors
30 comprised medical mistrust (of healthcare systems, government public health) and access
31 barriers due to unemployment, unstable housing, lack of transportation, no/low paid sick days,
32 low internet/digital technology access, and lack of culturally and linguistically appropriate
33 information. Social/community factors including trust in a personal healthcare provider (HCP),
34 altruism, family influence, and social proofing mitigated VH. At the individual level, low
35 perceived Covid-19 threat and negative vaccine attitudes were associated with VH.

36 **Discussion:** This review indicates the importance of identifying and disaggregating structural
37 factors underlying Covid-19 undervaccination among marginalized populations, both cross-

38 cutting and population-specific—including multiple logistical and economic barriers in access,
39 and systemic mistrust of healthcare systems and government public health—from individual and
40 social/community factors, including trust in personal HCPs/clinics as reliable sources of vaccine
41 information, altruistic motivations, and family influence, to effectively address individual
42 decisional conflict underlying VH as well as broader determinants of undervaccination.

43

44 **Keywords**

45 Vaccination hesitancy, Covid-19 vaccines, medical mistrust, social determinants of health,
46 access to care, ethnic and racial minorities

47 **Introduction**

48 Vaccination remains an essential component of public health strategies to control the
49 Covid-19 pandemic. Vaccination has reduced Covid-19-related morbidity and mortality in the
50 United States (U.S.) [1], and globally—with an estimated 63% (14.4–19.8 million) reduction in
51 deaths in the first year of Covid-19 vaccination alone [2]. Vaccine booster doses [3], and bivalent
52 vaccine boosters compared with past monovalent vaccination [4], have further reduced Covid-
53 19-associated hospitalization and death. Yet, despite the tremendous successes of Covid-19
54 vaccination, pervasive challenges ascribed to vaccine hesitancy (VH), and broader Covid-19
55 undervaccination, threaten the effectiveness of vaccines in controlling Covid-19 and other
56 vaccine-preventable diseases.

57 The World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE) on
58 Immunization defines vaccine hesitancy (VH) as “delay in acceptance or refusal of vaccination
59 despite availability of vaccination services” [5,p.4161]. In addition to individual-level correlates
60 of VH, SAGE [6] along with other research initiatives [7,8] have drawn attention to the critical
61 importance of vaccine availability and access—amid systematic variations in vaccine coverage
62 across countries and subpopulations—and issues that may pertain to specific vaccines.
63 Collectively, these challenges support the need to identify and examine multilevel factors that
64 contribute to Covid-19 VH and broader Covid-19 undervaccination (e.g., due to inaccessibility,
65 unavailability) [9].

66 Disparities in Covid-19 morbidity and mortality, as well as lower rates of Covid-19
67 vaccination, are well documented among marginalized populations in the U.S. [10-13].
68 Marginalization is defined by systemic processes driven by ideologies such as racism, sexism,
69 heterosexism, cissexism, ableism, and xenophobia, that exclude certain populations or relegate

70 them to the periphery of political and socioeconomic resources [14,15]. The structural and social
71 inequities produced by marginalization create adverse social determinants of health (SDOH)—
72 such as residential segregation and housing insecurity, employment precarity, income insecurity,
73 lack of access to affordable healthcare, barriers to physical mobility, and stigmatization—all of
74 which increase vulnerability to poor health outcomes [14]. Adverse SDOH exacerbate
75 vulnerability to Covid-19 through the disproportionate prevalence of underlying conditions
76 associated with worse Covid-19 outcomes, lower levels of health insurance and healthcare
77 access, and by impeding the ability to practice public health measures to reduce viral
78 transmission [16-19]. Although heightened vulnerability indicates an increased need for
79 vaccination, these same SDOH may contribute to *lower* levels of Covid-19 vaccination [20,21].
80 In fact, across 45 U.S. states, 0.1%–24.9% lower vaccination was documented among Blacks vs.
81 Whites, 0.0%–37.6% lower among Hispanics vs. Whites, as of May 2021—with state-level rate
82 differences significantly associated with a metric of structural racism [21]. In a national study,
83 eligible healthcare facilities and community pharmacies in counties with higher Black
84 composition were significantly less likely to provide Covid-19 vaccination [20].

85 Although some of the racial/ethnic disparities in Covid-19 vaccination documented
86 earlier in the pandemic have reportedly narrowed over time, attributed in part to the success of
87 targeted interventions [11], disparities persist in lower administration of booster doses among
88 Black, Hispanic/Latinx, and American Indian populations versus Whites [22]. Consistent with
89 the “inverse equity hypothesis,” with each innovation in Covid-19 vaccines, uptake is predicted
90 to be greater among wealthier and more socially connected segments of the population, thereby
91 increasing rather than reducing inequity [23,24]. Nevertheless, population-level disparities in
92 Covid-19 vaccination are often conceptualized as contingent on individual-level factors (e.g.,

93 low perceived threat, vaccine attitudes) to the relative underemphasis of structural and systemic
94 factors [20,21,25,26]. Moreover, trust/mistrust in a personal HCP as a source of reliable
95 information [27] is often conflated with systemic medical mistrust: distrust of healthcare
96 systems, government public health, medical treatments, and/or the pharmaceutical industry
97 arising from present-day experiences of discrimination and/or historical experiences of
98 discrimination and injustice in the healthcare system [28-30].

99 Building on the SAGE “Vaccine Hesitancy Determinants Matrix” and recommendations
100 to approach VH as a population- and context-specific phenomenon [6,31], along with critiques of
101 the lack of clarity in the definition and application of VH [32-34], we conducted a scoping
102 review to examine multilevel factors associated with Covid-19 VH and broader Covid-19
103 undervaccination among marginalized populations in the U.S.

104

105 **Methods**

106 A scoping review was conducted given our aim of mapping the evidence landscape [35]
107 on factors associated with Covid-19 VH and undervaccination among marginalized populations.

108 A scoping review protocol, including our search strategy and review process, has been
109 previously published [36]. We utilized the scoping review methodology described by Arksey and
110 O’Malley [37], further developed by the Joanna Briggs Institute [38], with all results reported in
111 accordance with PRISMA Extension for Scoping Reviews (PRISMA-ScR) guidelines [39].

112

113 **Research question**

114 This scoping review was guided by the question, “What are the determinants of Covid-19
115 ‘vaccine hesitancy’ reported among marginalized populations in the U.S. and Canada?”, with

116 sub-questions, “what are the focal populations in studies of Covid-19 VH and undervaccination
117 among marginalized populations?” and “what are the contexts and determinants of Covid-19 VH
118 and undervaccination by structural, social and community, individual, and vaccine-specific
119 factors?” [36].

120

121 **Information sources and search strategy**

122 We identified the following list of databases to search in consultation with a specialist
123 research librarian: Medline, Embase, Cochrane CENTRAL, Cochrane Covid-19 Study Register,
124 PsychINFO, Sociological Abstracts, and the International Bibliography of the Social Sciences
125 (IBSS). We then developed a search string with keywords and synonyms related to vaccine
126 hesitancy (i.e., “vaccine hesitancy”, “vaccine refusal”, “vaccine confidence”, “vaccine distrust”,
127 “vaccine mistrust”, “vaccine barriers”) and Covid-19 (i.e., “corona virus” or “coronavirus” or
128 “COVID” or “nCoV” along with adjacent terms “19” or “2019, or “SARS-CoV-2” or “SARS
129 Coronavirus 2”, etc.). S1 Table shows an example search string for Medline and Embase. We
130 adapted the search string to accommodate differences in syntax and parameters among the
131 selected databases.

132

133 **Study selection criteria**

134 We developed inclusion and exclusion criteria prior to conducting the search for peer-
135 reviewed articles published between January 1, 2020 and October 31, 2021: 1) populations in the
136 U.S. or Canada; 2) adults ≥ 18 years; 3) focused on (>50%) marginalized populations, 4) focused
137 on Covid-19 vaccine hesitancy, refusal, confidence, mistrust, or barriers. Articles were excluded
138 if they were 1) published prior to 2020; 2) not written in English; 3) focused on healthcare

139 workers, staff, or students/interns; or 4) focused on children (<18 years) or parents' vaccination
140 of children. We selected search dates corresponding to the declaration of Covid-19 as a public
141 health emergency through the initial authorization of Covid-19 vaccines for the adult population
142 in the U.S. and Canada in December 2020, until U.S. FDA and Health Canada recommendations
143 for the first booster vaccines, beginning in late September 2021 to early November 2021 [40,41].

144 We identified marginalized populations informed by a review of populations particularly
145 vulnerable to discrimination and exclusion in healthcare [42] or due to broader adverse SDOH
146 [14]. The populations include those marginalized in relation to their race or ethnicity, sexual
147 orientation or gender identity, physical or mental disability, persons living with HIV,
148 immigrants/refugees, persons who experience homelessness, justice-involved people, and people
149 who use drugs, along with their intersections (e.g., Latinx immigrants).

150

151 **Study selection process**

152 Search results of peer-reviewed articles were uploaded into Covidence software. Multiple
153 research team discussions ensured consistent application of inclusion/exclusion criteria. Initially
154 groups of two reviewers (among LR, TN, DD, KA, SF or ST) independently screened abstracts
155 and titles until we attained inter-rater reliability of 90% [43]; this was achieved after two rounds
156 of abstract review and team discussions to achieve consensus. Subsequently, in accordance with
157 rapid review methods, one reviewer screened each abstract/title to determine inclusion or
158 exclusion [44]. One reviewer (TN, DD, KA, SF or ST) then screened each full-text for inclusion.
159 Full-text articles designated for exclusion were then reviewed by a single arbitrator (PN), with
160 discrepancies resolved by consensus among the research team [44,45].

161

162 **Data extraction and synthesis**

163 We abstracted data on publication characteristics (i.e., author(s), study sites, sample size,
164 populations, methods, and domains of VH factors identified (see Table 1). We then reviewed the
165 abstracted data using quantitative (i.e., frequency) analysis to describe study locales, sample
166 sizes, focal populations, methods, and VH factor domains, and qualitative (i.e., narrative)
167 analysis to synthesize the evidence on VH and undervaccination among each subpopulation.

168 All authors categorized publications by domains of factors identified, using a four-
169 component framework informed by the “Vaccine Hesitancy Determinants Matrix” [6,31] and
170 recommendations to disaggregate multilevel phenomena [8,33,34]. Domains comprised
171 structural (e.g., access to vaccination site, medical mistrust); social/community (e.g., family
172 support, trust in personal HCP or clinic, social proofing [i.e., based on actions of others in one’s
173 community], community benefits); individual (e.g., perceived Covid-19 threat, perceived
174 transmission risk, general vaccine beliefs); and Covid-19 vaccine-specific factors (e.g., vaccine
175 safety, side effects, efficacy). One change to data extraction (but not inclusion) was made from
176 the initial protocol in that we differentiated between medical mistrust at the “system-level” and
177 trust in a personal HCP/clinic.

178

179 **Results**

180 The search captured 4,399 peer-reviewed articles in total, with 2,496 abstracts screened
181 after removal of duplicates. We identified 363 full-text articles to be screened for eligibility, with
182 a total of 50 peer-reviewed articles included [12,26,46-93]. The PRISMA flow diagram shows
183 the process of identifying relevant peer-reviewed journal articles (see Fig 1).

184

185 **Figure 1. PRISMA flow diagram for scoping review of COVID-19 vaccine hesitancy and**
186 **undervaccination among marginalized populations**

187

188 **Description of studies**

189 Among the 50 articles included, 86% were quantitative studies, 10% qualitative, and 4% mixed
190 methods (see Table 1). Sample sizes ranged from n=24 to n=164,283 (N=499,237; median=437).

191 All studies were conducted in the U.S., including 24 (48%) national studies, 8 (16%) in the West,
192 7 (14%) Northeast, 5 (10%) Midwest, 5 (10%) Southeast, and 1 (2%) in the Southwest region.

193 No studies were identified from Canada that met inclusion criteria within the timeframe of the
194 review.

195
196
197

Table 1. Study characteristics, focal populations, and domains of Covid-19 vaccine hesitancy and undervaccination among marginalized populations in the U.S., January 1, 2020 to October 31, 2021 (n = 50 articles)

Author(s)	Sample Size	Region	Study Setting	Focal Population(s)	Methods			Domains of VH			
					Quant	Qual	Mixed	Structural	Social/Community	Individual	Vaccine-specific
Allen	396	National	Online	Racial/ethnic min.	x				(+)		(-)
Arvanitis	601	MW	Telephone: Chicago, IL	Racial/ethnic min.	x			(-)		(+)	
Balasuriya	72	NE	Online: New Haven, CT	AA/Black & Latinx		x		(-)	(+)		
Battarbee	915	National	Online	Racial/ethnic min.	x			(-)	(+)		(-)
Bauer	3743	SW	Data obtained from the City of Brownsville Public Health Department	Latinx	x						
Bogart	101	W	Telephone: Los Angeles, CA	AA/Black and PLHA	x			(-)	(+)		(-)
Bogart	207	National	Online	AA/Black	x			(-)	(+)		(-)
Carson	70	W	Online: Los Angeles, CA	Racial/ethnic min.		x		(-)	(+/-)		(-)
Chin	97779	W	Data obtained from the CDCR vaccination program in California State Prisons	JI	x			(-)		(-)	(-)
Clark	224	MW	Clinic: Kansas City, MO	Racial/ethnic min.	x			(-)		(+)	(-)
Crozier	3721	SE	Telephone/Online: Alabama	AA/Black	x			(-)			
Ehde	486	National	Online	PWD	x			(+)	(+)	(+)	
Ehde	359	National	Online	PWD	x			(+)		(+)	(-)
Fernandez-Penny	1068	NE	Hospitals: Philadelphia, PA	AA/Black	x			(-)	(+)		(-)

Fisher	1668	National	Online	Racial/ethnic min.	x				(+)		
Garcia	1515	National	Online: US Hemodialysis Facilities	Racial/ethnic min.	x				(+/-)	(-)	(-)
Garcia	46	W	Telephone: OR	Latinx		x		(-)	(+)		(-)
Geana	25	MW	Telephone: Midwest USA	JI		x		(-)	(-)	(-)	(-)
Ghaffari-Rafi	359	W	Telephone: HI	PWD	x			(-)	(-)	(+)	(-)
Guidry	788	National	Online	Racial/ethnic min.	x			(-)			(-)
Hagan	164,283	National	Data obtained from Electronic Medical Records in Federal Bureau of Prisons	JI	x			(+/-)	(+)	(-)	(+)
Iadarola	825	NE	Online: NY	PWD	x			(-)	(-)	(-)	(-)
Jimenez	111	NE	Online: NJ	AA/Black & Latinx	x			(-)	(-)		(-)
Johnson	248	SE	Clinic: Baton Rouge, LA	AA/Black	x			(-)	(-)		(-)
Jones	94	SE	Telephone/Online: Miami, FL	PLHA	x			(-)	(+)	(+/-)	(-)
Kricorian	1950	National	Online	AA/Black & Latinx	x			(-)	(+)		(-)
Kuhn	90	W	Telephone: Los Angeles, CA	PEH	x			(-)	(-)	(-)	(-)
Luo	6715	National	Data obtained from the Medicare Current Beneficiary Survey	PWD	x			(-)		(+)	(-)
Masson	258	W	California residential substance use treatment programs	PWUD	x			(-)		(+)	(-)
Momplaisir	24	NE	Online: Philadelphia, PA	AA/Black		x		(-)	(+/-)	(-)	(-)
Moore	257	SE	Community Events: The Central Savannah River Area	AA/Black	x			(-)		(-)	
Myers	439	National	Online	PWD	x			(-)	(+)	(+)	(-)
Okoro	183	MW	Online: MN and WI	AA/Black			x	(-)	(+/-)	(-)	(-)
Razzaghi	135,968	National	Data obtained from the Vaccine Safety Datalink (VSD)	Racial/ethnic min.	x			(-)			(-)

Rodriguez	2301	National	Emergency Departments in Hospitals	Racial/ethnic min.	x			(-)	(-)		(-)
Rodriguez	175	SE	Online: Miami, FL	PLHA	x			(-)	(+)	(-)	(-)
Rungkitwattanukul	90	National	Hemodialysis centres	AA/Black	x			(-)	(-)	(-)	(-)
Ryerson	56,749	National	Telephone	PWD	x			(-)	(+)	(+)	
Salmon	2525	National	Online	Racial/ethnic min.	x			(-)	(+/-)	(+)	(-)
Stephenson	290	National	Data obtained from the Love and Sex in the Time of COVID-19 study	LGBTQ+	x				(+)	(+)	
Stern	5110	National	Correctional and detention facilities	JI	x			(-)	(-)	(-)	(-)
Stoler	1040	National	Online	AA/Black	x			(-)	(+)		
Teixeira da Silva	1350	National	Online	LGBTQ+	x			(-)	(+/-)		(-)
Tsapepas	664	NE	Telephone: New York City, NY	Racial/ethnic min.			x	(-)			(-)
Uhr	701	National	Online	PWD	x			(+/-)	(+)	(-)	(-)
Wagner	1138	MW	Data obtained from the Detroit Metro Area Community Study	AA/Black	x			(-)			(-)
Wang	293	NE	Online: DE	AA/Black	x			(-)			(-)
Xiang	401	W	Online: Mainly OR, WA, and CA	PWD	x				(+/-)	(+)	(-)
Yang	387	National	Online	PWUD	x			(-)	(+/-)	(-)	(+)
Zhang	435	National	Online: Refugee communities	IMM	x			(-)	(+)		(-)

198 AA, African Americans; IMM, immigrants and refugees; JI, justice-involved people; Latinx, Latinx/Hispanic people; LGBTQ+,
199 Lesbian, gay, bisexual, transgender, queer and other sexual/gender minority people; PEH, people experiencing homelessness; PWD,
200 people with disabilities; PLHA, people living with HIV/AIDS; PWUD, people who use drugs; Racial/Ethnic min., racial/ethnic
201 minority.

202 Table 2 shows the number of focal articles by subpopulation, with 11 (22%) focused on
203 African American/Black people, 9 (18%) on people with disabilities, 4 (8%) on justice-involved
204 people, and 2 (4%) each on Latinx, people living with HIV/AIDS (PLHA), people who use drugs
205 (PWUD), and lesbian, gay, bisexual, transgender, and queer (LGBTQ+) people. We allocated
206 findings from articles broadly focused on racial/ethnic minorities to each of the subpopulations
207 (i.e., African American/Black, Latinx, Asian, American Indian) for which disaggregated data
208 were provided (i.e., one article could be a “source” for several populations). Four additional
209 articles addressing VH pertaining to two subpopulations (e.g., African American/Black PLHA)
210 were each allocated as two sources. Table 2 shows the total number of sources (n=73) addressing
211 population-specific factors associated with VH across the 50 articles. Among these, 41.1% of
212 sources (n=30) identified VH factors among African American/Black populations, 17.8% (n=13)
213 Latinx populations, 12.3% (n=9) people with disabilities, and 5.5% (n=4) each Asian, justice-
214 involved, and PLHA.

215 **Table 2. Focal articles and additional sources by subpopulation**

Subpopulation	Focal articles on each sub-population	Additional sources addressing each subpopulation	Number (%) of total sources by sub-population (n=73)
African American/Black	11	19	30 (41)
Latinx	2	11	13 (18)
People with disabilities	9	0	9 (12)
Justice involved	4	0	4 (5)
People living with HIV/AIDS	2	2	4 (5)
Asian people	0	4	4 (5)
People who use drugs	2	1	3 (4)
Immigrants/refugees	1	1	2 (3)
LGBTQ+ people	2	0	2 (3)
People experiencing homelessness	1	0	1 (1)
American Indians/Native	0	1	1 (1)
Subtotal	34	39	73

216 LGBTQ+, Lesbian, gay, bisexual, transgender, queer and other sexual/gender minority people

217

218 Fig 2 shows the number of articles addressing factors associated with VH in each of four
 219 domains: structural, social/community, individual, and Covid-19-vaccine-specific. Table 3 shows
 220 the domains of factors associated with VH in each subpopulation. Next, we describe findings
 221 based on a narrative synthesis of factors associated with VH and undervaccination for each focal
 222 population.

223
 224 **Fig 2. Count of articles identifying factors in each of the four domains of Covid-19 vaccine**
 225 **hesitancy and underutilization**

226
 227 **Table 3. Population by domains of factors identified in Covid-19 vaccine hesitancy and**
 228 **undervaccination**

Subpopulation	Domains			
	Structural	Social/Community	Individual	Vaccine-specific
African American/Black	x	x	x	x
American Indian/Native American	x			x
Asian	x	x		x
Latinx	x	x		x
LGBTQ+	x	x	x	x
Immigrant/Refugee	x	x		x
Justice-involved people	x	x	x	x
People experiencing homelessness	x	x	x	x
People living with HIV/AIDS	x	x	x	x
People with disabilities	x	x	x	x
People who use drugs	x		x	x

229 LGBTQ+, Lesbian, gay, bisexual, transgender, queer and other sexual/gender minority people

230 ***Black and African American people***

231 Eleven articles focused exclusively on Covid-19 vaccination among Black/African
232 Americans [26,56,59,69,74,75,77,81,85,89,90], and 19 additional articles provided disaggregated
233 data—a total of 30 sources [46-48,49,51-53,55,60,65-68,70,73,82,84,86,92]. At the structural
234 level, 27 sources addressed the negative impacts of medical mistrust and distrust of government
235 on Covid-19 vaccination among Black and African Americans [26,46-49,51-53,55,59,65-70,73-
236 75,77,81,82,84-86,89,92]. Several studies described Covid-19 VH, such as due to fears of being
237 experimented on with Covid-19 vaccines without consent, “based on...knowledge of historic
238 mistreatment and unethical research practices that adversely impacted black patients and
239 participants” [74, p.1786], including the legacy of the Tuskegee Study of untreated syphilis
240 [53,67,68,77]. Eleven sources addressed barriers to present-day healthcare and Covid-19
241 vaccines for Black/African Americans, including unemployment, housing insecurity, limited
242 interactions with HCP, and difficulties travelling to vaccination sites [48,52,53,56,68-
243 70,75,77,89,90].

244 At the social/community level, nine sources indicated the role of trust in HCPs in Covid-
245 19 vaccination intentions [26,46,51,60,69,70,74,82,85]. Characteristic of many studies, "Blacks
246 and Hispanics were more likely than Whites to state that it was ‘extremely’ important that a
247 medical professional of their same race/ethnicity endorse the vaccine before they took it”
248 [26,p.8]. Seven studies addressed the influence of families and communities on Covid-19
249 vaccination [48,52,59,70,74,77,81], and further that “governmental agencies are less well-
250 received as information sources compared to friends or family” [59, p.1103]. In one study,
251 family influence promoted VH by casting doubt on public health information, rather than
252 motivating vaccination [81].

253 At the individual level, four studies addressed negative impacts of religious beliefs,
254 including preference for ‘natural’ medicines over vaccines, and general vaccine aversion on
255 Covid-19 vaccination [67,74,77,81]. Covid-19 vaccine-specific concerns, identified in 14
256 studies, included vaccine safety, adverse effects, and uncertain efficacy [26,51-53,59,67-
257 70,73,74,77,81,90], and the importance of evidence of Covid-19 vaccine safety and efficacy
258 specific to Black/African Americans: “any data that’s connected with some of the conditions that
259 are prevalent in our community” [53, p.8].

260

261 *Latinx/Hispanic people*

262 Two studies focused on Covid-19 vaccination among Latinx/Hispanic people [50,61],
263 with an additional 11 sources providing data specific to this population
264 [26,46,48,49,53,60,67,68,70,73,82]. At the structural level, five studies identified negative
265 impacts of medical mistrust [48,49,61,67,82], including fear of being used as “guinea pigs
266 (conejillos de indias)” and of being sterilized [61]. Limited access to information in one’s
267 preferred language, complicated online vaccination sign-up procedures, lack of insurance, and
268 lack of transportation to vaccination sites posed barriers to Covid-19 vaccination
269 [48,53,61,68,70]. Two studies underscored the importance of tailored vaccine education and
270 accessible information [68]: “[a family member] doesn’t speak English...so, a lot of the
271 information that he may have heard about the vaccine and Covid probably came off of Univision
272 and Telemundo” [48, p.6].

273 At the social/community level, five studies described the important role of personal HCPs
274 in Covid-19 vaccination among Latinx communities [26,46,60,70,82], including endorsement
275 from an HCP of one’s own ethnicity [26]. Two studies addressed altruism and wanting to protect

276 one's community as a motivator of Covid-19 vaccination [53,61]. Families and close
277 communities were described as playing an important role in Covid-19 vaccination knowledge
278 and decision-making [48,61,70]: "79% of the youth had discussed health with their families for
279 an average of 50 minutes [per week]" [61, p.753]. No individual-level factors were described,
280 but Covid-19 vaccine-specific concerns arose around safety, adverse effects, and efficacy
281 [26,61,67,68,70,73].

282

283 *Asian people*

284 No studies focused exclusively on Covid-19 vaccination among people of Asian descent
285 in the U.S.; four sources provided disaggregated data on Asian people [46,53,64,67]. At the
286 structural level, barriers included difficulties in accessing reliable translations and messengers of
287 Covid-19 vaccine information [53]. Beyond linguistic translation, a Filipinx participant
288 explained, "In terms of translators...maybe those who may not be of the same culture or the way
289 that they're explaining the medical terminology may be intimidating" [53, p.6]. Medical mistrust
290 was identified as negatively impacting vaccination intention [53,67], with trust in personal HCPs
291 as sources of vaccine information positively associated with Covid-19 vaccination intention
292 among Asian people [46]. Covid-19 vaccine-specific concerns arose around safety, adverse
293 effects, and efficacy [53,64,67], including the need for population-specific evidence: "There has
294 been a lot of concerns in my family on how the vaccine works for people with heart disease,
295 which really affects...a lot of the Filipino community, and also those with respiratory diseases"
296 [53, p.6].

297

298

299 ***American Indians***

300 No studies among those reviewed focused on Covid-19 vaccination among American
301 Indians or Alaskan Natives; one source provided data on American Indians [53]. Structural
302 factors arose regarding distrust of government, desire for autonomy (“to be respected”),
303 challenges in access to digital technology and the internet, lack of quality translations and
304 tailored information, lack of employment benefits, insurance, and transportation to get
305 vaccinated [53]. In addition to distrust ascribed to the politicization of vaccination, a participant
306 decried structural-level challenges for elders: “Some elders...they’re houseless...there’s no cell
307 phone, they ride public transportation. How is it going to get distributed [to them]...the most
308 vulnerable... it feels like our culture always gets the shitty end of the stick” [53, p.6]. Covid-19
309 vaccine-specific concerns arose around side effects, efficacy, and multiple doses—associated
310 with challenges for Native families due to the need for several trips to vaccination sites.

311

312 ***LGBTQ+ people***

313 Two sources focused on Covid-19 vaccination among LGBTQ+ people [83,86]. At the
314 structural level, medical mistrust based on historical discrimination against sexual and gender
315 minorities was negatively associated with Covid-19 vaccination intentions [86]. Loss of
316 employment and housing insecurity were described as factors that underscored the threat of the
317 pandemic among LGBTQ+ people, thus motivating vaccination. At the social and community
318 level, altruistic motivations were positively associated, while anticipated stigma was negatively
319 associated with vaccination intentions [83,86]. Individual-level factors impacting vaccination
320 were described in perceived threat of Covid-19: “negative experiences, along with the reported
321 high levels of perception of the seriousness of Covid-19 infection, are likely driving the high

322 levels of willingness to be vaccinated” [83,p.9]. Covid-19 vaccine-specific concerns included
323 adverse effects and safety [86].

324

325 *People with disabilities*

326 Nine articles focused on challenges in Covid-19 vaccination for people with disabilities
327 (PWD) [12,57,58,64,67,72,76,88,91]. At the structural level, five studies addressed the impact of
328 trust in government: three reported a positive association with Covid-19 vaccination [57,58,88],
329 while two described governmental distrust contributing to VH [67,72]. Strict public health
330 measures and widespread reliance on digital technology during the pandemic posed structural
331 barriers in access to Covid-19 vaccination for PWD [12,72,76,88]. While PWD were described
332 as more likely than people without a disability to endorse Covid-19 vaccination, they were more
333 likely to report difficulties booking online vaccination appointments and locating and travelling
334 to vaccination sites [12].

335 At the social and community level, having a trusted HCP or clinic exerted a positive
336 influence on Covid-19 vaccination [12,57,76,88,91]. For example, among people living with
337 multiple sclerosis (MS), MS-specialist HCPs and the National MS Society were deemed trusted
338 sources: “well-positioned to provide accurate education about Covid-19 disease and vaccine
339 considerations...specific to the MS population as well as their individual patients” [57,p.3].

340 At the individual level, perceived threat of Covid-19 was a positive correlate of Covid-19
341 vaccination among PWD, including individuals with chronic diseases and multiple comorbidities
342 [12,57,58,64,72,76,91]. Covid-19 vaccine-specific concerns included adverse effects, speed of
343 vaccine development, vaccine safety, and efficacy [58,64,67,72,76,88,91]. In addition to “safety
344 and efficacy...the top Covid-19 vaccination concerns”, apprehension arose around “the effect of

345 the vaccine on MS symptoms and implications for [immunosuppressive] DMT [disease-
346 modifying therapy] use” [88, p.1078].

347

348 *Justice-involved people*

349 Four articles focused on Covid-19 vaccination among justice-involved (JI) individuals
350 (i.e., currently or formerly convicted or incarcerated) [54,63,66,84]. At the structural level,
351 medical mistrust and distrust of government exerted a negative impact on Covid-19 vaccination
352 among individuals in detention facilities [54,63,84] “based on their interactions with law
353 enforcement or the justice system or their experiences with institutional racism” [84, p.476]. A
354 study with incarcerated women described “a direct correlation between trust in the
355 pharmaceutical industry and willingness to receive the vaccine”: “I’ve watched too many people
356 die because pharmaceuticals... So I don’t know. Pharmaceutical companies just see a lot of big
357 money in there” [63, p.895]. One study described mitigation of structural-level barriers to Covid
358 -19 vaccination through tailored vaccine education and “early access to vaccine through a
359 dedicated federal allocation” for incarcerated individuals and facility staff [66,p.5889].

360 At the social and community level, family and community influence was associated with
361 Covid-19 VH [54,63,66] among JI individuals in the absence of tailored public health
362 messaging: “The probable low health and informational literacy of these women leave them
363 vulnerable to influence from family and friends, many sharing and promoting disinformation and
364 conspiracy theories frequently shared by homegrown anti-vaccine organizations” [63, p.895].
365 Social proofing exerted a positive influence: “some people may have been encouraged to accept
366 vaccination because they could see their peers being vaccinated” [54,66, p.5889].

367 At the individual level, all four studies reported low perceived risk of contracting Covid-

368 19 as a correlate of VH among JI people [54,63,66,84]. A study in correctional and detention
369 facilities in 4 states reported that of participants (n=1823/5110) who would refuse Covid-19
370 vaccination, 18.9% (n=344/1823) “did not perceive themselves to be at risk for Covid-19 or
371 thought vaccination was unnecessary” [84, p.475]. Covid-19 vaccine-specific concerns arose
372 around vaccine safety and efficacy [54,63,84], which was associated with “lack of access to
373 reliable information” [54, p.375].

374

375 *People living with HIV/AIDS*

376 Two articles focused on factors impacting Covid-19 vaccination intentions among PLHA
377 [70,80], with two additional sources providing PLHA-specific data [51,83]. At the structural
378 level, medical mistrust and distrust of government among PLHA were associated with lower
379 Covid-19 vaccination intentions [51,70,80]. A study with HIV-positive and predominantly
380 sexual minority Black Americans (n=101) indicated that “The most prevalent general mistrust
381 beliefs (endorsed by about half or more than half) concerned withholding information or a lack
382 of honesty by the government,” which was correlated with VH [51, p.203]. A study with HIV-
383 positive Black and Latinx Americans described unemployment being exacerbated by the
384 pandemic, with negative impacts on access to healthcare and Covid-19 vaccination [70]. At the
385 social and community level, the positive influence of personal HCPs as trusted sources of
386 information on Covid-19 vaccination was reported [51,70,80]: “Lower hesitancy scores were
387 present in participants who reported that they would get vaccinated if their provider
388 recommended it” [80, p.98].

389 At the individual level, perceived threat was associated with Covid-19 vaccination
390 intentions: “...HIV-positive men may have more concerns about the seriousness and perceived

391 impact of Covid-19 infection on their health” [80, 83, p.9]. Covid-19 vaccine-specific concerns
392 arose around vaccine safety, adverse effects, and efficacy [51,70,80], with some PLHA
393 concerned that their health condition may make Covid-19 vaccination unsafe [80].

394

395 ***People who use drugs***

396 Two studies focused on Covid-19 vaccination among people who use drugs (PWUD)
397 [73,92], with one additional source providing disaggregated data on PWUD [64]. At the
398 structural level, barriers to accessing healthcare and Covid-19 vaccines, as well as medical
399 mistrust and distrust in government were associated with lower Covid-19 vaccination intentions
400 [64,73]. One study noted vulnerability to misinformation among PWUD amid medical mistrust:
401 “As a marginalized population, patients with illicit drug use are often detached from and mistrust
402 the healthcare system—by extension, these patients may be more reliant on illegitimate
403 information sources” [64, p.803]. At the individual level, mask wearing was associated with
404 vaccine trust, both described as a function of accurate Covid-19 information [73]. Covid-19
405 vaccine-specific factors arose around safety and efficacy concerns that may negatively impact
406 uptake [73].

407

408 ***Immigrants and refugees***

409 One study focused on Covid-19 vaccination among immigrants and refugees [93], with
410 one additional source providing disaggregated data [61]. At the structural level, barriers to
411 healthcare and Covid-19 vaccine access were described as negatively impacting vaccination
412 [61,93]. A study with Latinx immigrant families identified “fear of encountering law
413 enforcement/immigration as barriers to access health care” [61, p.750]. Limited access to

414 information in one’s preferred language, lack of reliable information from trusted sources,
415 constraints in access to the internet and digital technology, and lack of transportation and
416 employment benefits (i.e., paid sick days) were identified as barriers to Covid-19 vaccination
417 [93]. At the social and community level, family influence was demonstrated in a national online
418 survey of refugees (n=435): among those who reported intention to receive a Covid-19 vaccine,
419 nearly two-thirds (65.0%; n=199/306) indicated that it was motivated in part to protect their
420 family members [93]. Covid-19 vaccine-specific concerns about vaccine safety, adverse effects,
421 and efficacy were associated with VH, with two-thirds (71.3%; n=92/129) of refugees who
422 reported no intention or being unsure of accepting Covid-19 vaccination indicating concerns
423 about adverse effects [93].

424

425 *People experiencing homelessness*

426 One article focused on challenges to Covid-19 vaccination for people experiencing
427 homelessness [71]. At the structural level, Covid-19 VH was described as a function of “a more
428 general distrust of systems (e.g., health and homeless services) that are not designated to meet
429 their needs” [71, p.6]. Trusting the information received from friends, family, and social media
430 rather than “official news sources” was associated with greater Covid-19 VH [71]. At the
431 individual level, general vaccine aversion and low Covid -19 risk perception, and vaccine-
432 specific concerns about safety, adverse effects, and efficacy were associated with VH among
433 people experiencing homelessness [71].

434

435 **Discussion**

436 This scoping review of Covid-19 vaccine hesitancy and broader underutilization of

437 Covid-19 vaccination provides evidence of multilevel determinants of delays or refusal of Covid-
438 19 vaccination across marginalized populations in the U.S. Overall, a preponderance of
439 structural-level factors were identified that impact Covid-19 vaccination across marginalized
440 populations. Logistical and economic constraints including lack of transportation to distant
441 locales, lack of paid sick days, lack of availability of vaccination at familiar/local community
442 venues, and barriers in access due to being unemployed, unstably housed,
443 uninsured/underinsured, and the digital divide (i.e., access to digital technology and the internet,
444 and technical and financial ability to utilize it [94]) were compounded by lack of culturally and
445 linguistically appropriate information and access to trusted HCPs. Collectively, these findings
446 suggest that approaches to undervaccination among marginalized populations that focus
447 predominantly on individual-level, psychological factors may fail to capture the breadth and
448 impact of determinants of Covid-19 vaccination.

449 Importantly, we identified evidence for differential impacts of medical mistrust, as a
450 structural factor [29], and trust in a personal HCP or clinic, as a social/community factor. The
451 influence of medical mistrust reported with respect to government public health, healthcare
452 systems, and the pharmaceutical industry, emerged across multiple marginalized populations—
453 including African American, Latinx, LGBTQ+ populations, and their demographic
454 intersections—attributed in part to historical discrimination and past unethical medical research
455 and interventions, as well as present-day discrimination in healthcare and government
456 institutions. Nevertheless, having a trusted HCP, particularly with shared race or ethnicity
457 [26,51,69,70,74,82,85], or a familiar source of primary healthcare, mitigated Covid-19 VH—
458 despite broader mistrust of healthcare systems and government public health. JI populations,
459 PEH, and PWUD expressed medical mistrust due to generally negative experiences with

460 government and healthcare institutions. However, as in the case of JI populations, proactive
461 interventions to promote tailored education along with policy decisions to prioritize Covid-19
462 vaccination in prisons served to mitigate VH and promote vaccination [66].

463 Personal HCPs and usual care venues were widely reported to assuage concerns and
464 reduce VH, indicating a crucial role for primary healthcare [95]. In this light, the absence of
465 information from trusted sources tailored to address healthcare needs experienced as most
466 relevant to one’s own community—reported among Black and Pilipino populations, PLHA and
467 PWD—and the lack of availability of Covid-19 and vaccine information in one’s primary
468 language (reported among Latinx, Asian, and immigrant/refugee populations) emerged as
469 substantial missed opportunities to promote Covid-19 vaccination. Access to Covid-19
470 vaccination from a known HCP or clinic may be particularly important for marginalized
471 communities, who are more predisposed towards medical mistrust due to negative interactions
472 with the healthcare system and other societal institutions, and more vulnerable to discrimination
473 in healthcare [96,97].

474 Overall, the conflation of structural factors—documented in multifaceted barriers in
475 access to Covid-19 vaccination and systemic mistrust of healthcare systems—with individual
476 and social/community factors, such as perceived threat of Covid-19, perceived risk of
477 transmission, general vaccine attitudes, endorsement from one’s personal HCP, and family
478 influence, each of which may impact on “decisional conflict” more specifically aligned with VH
479 [32], may fail to foster solutions that effectively address the identified problems [34,95,98].
480 Moreover, the attribution of structural-level barriers to individual volition and deficits may
481 exacerbate alienation and mistrust among populations already marginalized due to systemic
482 discrimination, stigma, and adverse SDOH [96].

483 Interestingly, some of the same ostensible factors showed negative or positive
484 associations with VH depending on the population and context. For example, family influence
485 exerted a positive impact on Covid-19 vaccination among Latinx communities and
486 immigrant/refugee populations through familial sharing of health information and desire to
487 protect one’s family. However, among other populations, the context of medical mistrust and the
488 virtual vacuum created by the absence of access to culturally tailored public health information
489 rendered family influence a liability, resulting in promulgation of conspiracy theories and
490 mistrust of Covid-19 vaccines among some African Americans [81], PEH [71], and JI persons
491 [63]. These examples underscore the importance of approaching VH as a population-specific and
492 context-dependent phenomenon [6,7]—in addition to disentangling the assessment of systemic
493 factors from individual-level and social/community concerns [99]. Consequently, the same
494 intervention applied to what might be understood as the same factor may exert opposite effects
495 on Covid-19 VH across different populations.

496 Finally, facilitators of Covid-19 vaccination emerged despite constraints. For example,
497 findings in common across PLHA and PWD—among whom one might reasonably expect
498 heightened concerns about vaccination due to underlying comorbidities and potential interactions
499 with routine medications—included the benefits of regular contact with a personal HCP or clinic;
500 this promoted trust in the vaccine information received and confidence in the HCP’s ability to
501 address population-specific concerns. Furthermore, intersectional strengths reported regarding
502 Latinx immigrant and refugee populations included motivations to protect one’s community and
503 cultural norms around familial sharing of health information, which served to mitigate VH.
504 Beyond a deficit model, community assets and sociocultural facilitators may be leveraged [100]
505 to support Covid-19 vaccination.

506 Findings from this scoping review should be understood in the context of limitations.
507 First, as a scoping review, our objective was to map and synthesize evidence on Covid-19 VH
508 and undervaccination among marginalized populations; we cannot draw causal conclusions about
509 the associations identified, nor was our aim to quantify Covid-19 vaccination intentions or
510 uptake, more apropos of meta-analysis. However, our scoping review methods reveal nuanced
511 information through synthesis of quantitative and qualitative findings on population-specific
512 barriers to Covid-19 vaccination and suggest important directions for future research. Second,
513 additional populations to those included might be characterized by marginalization, although we
514 based our focal populations on previous evidence and a priori criteria [42,43]. Third, while our
515 initial search comprised studies from the U.S. and Canada, no studies were identified from
516 Canada that met inclusion criteria during the specified time frame, possibly due to the later
517 availability of Covid-19 vaccination to the general adult population [41]. Studies published after
518 the time frame of our review might include additional populations, data, and study locales,
519 although we purposely focused on the initial introduction of Covid-19 vaccines before
520 subsequent booster doses and bivalent vaccines. Lastly, factors associated with VH and
521 underutilization of monovalent and bivalent boosters may differ from those revealed for initial
522 Covid-19 vaccination, although vaccine inequities remain [23].

523 In conclusion, we identified multilevel factors that influence Covid-19 VH and broader
524 underutilization of Covid-19 vaccination, several of which may apply to other vaccinations. This
525 scoping review suggests that distinguishing among individual and social/community factors that
526 may fuel decisional ambivalence characteristic of Covid-19 VH—“a state of indecision and
527 uncertainty about vaccination before a decision is made to act (or not act)” [35, p.58]—and
528 factors attributable to systemic and structural barriers in access to vaccination and historically-

529 justified mistrust of healthcare institutions, government public health, and the pharmaceutical
530 industry, may support evidence informed strategies to promote Covid-19 vaccination among
531 marginalized communities. Nevertheless, distilling and applying lessons from Covid-19
532 vaccination to effectively and equitably address VH and broader challenges in vaccine access
533 may be contingent on resourcing and scaling up community partnerships and local health
534 infrastructures [23,25,96,100], national population-specific public health initiatives to promote
535 vaccination [101,102], and structural reforms beyond those traditionally associated with public
536 health.

537 **Acknowledgements**

538 We would like to thank Nalini Singh, University of Toronto Research Librarian, for assistance in
539 designing the literature search strategy and Dares Wotansirigul for uploading sources into
540 Covidence software.

541

542 **Funding**

543 This work was supported by the Canadian Institutes of Health Research [GA3-177731].

544

545 **Declaration of competing interest**

546 The authors declare the following financial interests/personal relationships which may be
547 considered as potential competing interests: Peter A. Newman is a member of the Editorial
548 Board of PLOS ONE.

549

550 **References**

- 551 1. Steele MK, Couture A, Reed C, Iuliano D, Whitaker M, Fast H, et al. Estimated number of
552 COVID-19 infections, hospitalizations, and deaths prevented among vaccinated persons in
553 the US, December 2020 to September 2021. *JAMA Netw Open*. 2022;5(7):e2220385.
554 <https://doi.org/10.1001/jamanetworkopen.2022.20385>
- 555 2. Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the
556 first year of COVID-19 vaccination: a mathematical modelling study. *Lancet Infect Dis*.
557 2022;22(9):1293-302. [https://doi.org/10.1016/S1473-3099\(22\)00320-6](https://doi.org/10.1016/S1473-3099(22)00320-6)
- 558 3. Arbel R, Hammerman A, Sergienko R, Friger M, Peretz A, Netzer D, Yaron S. BNT162b2
559 vaccine booster and mortality due to Covid-19. *N Engl J Med*. 2021;385(26):2413-20.
560 <https://www.nejm.org/doi/10.1056/NEJMoa2115624>
- 561 4. Surie D, DeCuir J, Zhu Y, Gaglani M, Ginde AA, Douin DJ, et al. Early estimates of
562 bivalent mRNA vaccine effectiveness in preventing COVID-19–associated hospitalization
563 among immunocompetent adults aged ≥ 65 Years — IVY Network, 18 States, September
564 8–November 30, 2022. *MMWR Morb Mortal Wkly Rep*. 2022;71(5152):1625-30.
565 <http://dx.doi.org/10.15585/mmwr.mm715152e2>
- 566 5. MacDonald NE; SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy:
567 definition, scope and determinants. *Vaccine*. 2015;33(34):4161-4.
568 <https://doi.org/10.1016/j.vaccine.2015.04.036>
- 569 6. SAGE Working Group. Report of the SAGE Working Group on vaccine hesitancy.
570 Geneva: WHO; 2014 Nov 12. Available from: [https://www.asset-](https://www.asset-scienceinsociety.eu/sites/default/files/sage_working_group_revised_report_vaccine_hesitant.pdf)
571 [scienceinsociety.eu/sites/default/files/sage_working_group_revised_report_vacchan-](https://www.asset-scienceinsociety.eu/sites/default/files/sage_working_group_revised_report_vaccine_hesitant.pdf)
572 [cy.pdf](https://www.asset-scienceinsociety.eu/sites/default/files/sage_working_group_revised_report_vaccine_hesitant.pdf) [accessed 4 January 2023].

- 573 7. Larson HJ, Clarke RM, Jarrett C, Eckersberger E, Levine Z, Schulz WS, et al. Measuring
574 trust in vaccination: a systematic review. *Hum Vaccin Immunother.* 2018;14(7):1599-609.
575 <https://doi.org/10.1080/21645515.2018.1459252>
- 576 8. Thomson A, Robinson K, Vallée-Tourangeau G. The 5As: a practical taxonomy for the
577 determinants of vaccine uptake. *Vaccine.* 2016;34(8):1018-24.
578 <https://doi.org/10.1016/j.vaccine.2015.11.065>
- 579 9. Gostin LO, Hodge JG Jr, Bloom BR, El-Mohandes A, Fielding J, Hotez P, et al. The public
580 health crisis of underimmunisation: a global plan of action. *Lancet Infect Dis.*
581 2020;20(1):e11-6. [https://doi:10.1016/S1473-3099\(19\)30558-4](https://doi:10.1016/S1473-3099(19)30558-4)
- 582 10. Baack BN, Abad N, Yankey D, Kahn KE, Razzaghi H, Brookmeyer K, et al. COVID-19
583 vaccination coverage and intent among adults aged 18-39 years - United States, March-
584 May 2021. *MMWR Morb Mortal Wkly Rep.* 2021;70(25):928-33.
585 <http://dx.doi.org/10.15585/mmwr.mm7025e2>
- 586 11. Kriss JL, Hung MC, Srivastav A, Black CL, Lindley MC, Lee JT, et al. COVID-19
587 vaccination coverage, by race and ethnicity - National Immunization Survey Adult COVID
588 Module, United States, December 2020-November 2021. *MMWR Morb Mortal Wkly Rep.*
589 2022;71(23):757-63. <http://dx.doi.org/10.15585/mmwr.mm7123a2>
- 590 12. Ryerson AB, Rice CE, Hung MC, Patel SA, Weeks JD, Kriss JL, et al. Disparities in
591 COVID-19 vaccination status, intent, and perceived access for noninstitutionalized adults,
592 by disability status - National Immunization Survey Adult COVID Module, United States,
593 May 30-June 26, 2021. *MMWR Morb Mortal Wkly Rep.* 2021;70(39):1365-71.
594 <https://doi.org/10.15585/mmwr.mm7039a2>

- 595 13. Shariff SZ, Richard L, Hwang SW, Kwong JC, Forchuk C, Dosani N, et al. COVID-19
596 vaccine coverage and factors associated with vaccine uptake among 23,247 adults with a
597 recent history of homelessness in Ontario, Canada: a population-based cohort study. *Lancet*
598 *Public Health*. 2022;7(4):e366-77. [https://doi.org/10.1016/s2468-2667\(22\)00037-8](https://doi.org/10.1016/s2468-2667(22)00037-8)
- 599 14. Baah FO, Teitelman AM, Riegel B. Marginalization: conceptualizing patient vulnerabilities
600 in the framework of social determinants of health—an integrative review. *Nurs Inq*.
601 2019;26(1):e12268. <https://doi.org/10.1111/nin.12268>
- 602 15. Sharma M. Developing an integrated curriculum on the health of marginalized populations:
603 successes, challenges, and next steps. *J Health Care Poor Underserved*. 2014;25(2):663-9.
604 <https://doi.org/10.1353/hpu.2014.0102>
- 605 16. Lau DT, Sosa P. Disparate impact of the COVID-19 pandemic and health equity data gaps.
606 *Am J Public Health*. 2022;112(10):1404-6. <https://doi.org/10.2105/AJPH.2022.307052>
- 607 17. World Health Organization. COVID-19 and the social determinants of health and health
608 equity: evidence brief. Geneva: WHO, Dec 6, 2021. Available from:
609 <https://www.who.int/publications/i/item/9789240038387> [accessed 5 January 2023].
- 610 18. Mackey K, Ayers CK, Kondo KK, Saha S, Advani SM, Young S, et al. Racial and ethnic
611 disparities in COVID-19-related infections, hospitalizations, and deaths: a systematic
612 review. *Ann Intern Med*. 2021;174(3):362-73. <https://doi.org/10.7326/M20-6306>
- 613 19. Mude W, Oguoma VM, Nyanhanda T, Mwanri L, Njue C. Racial disparities in COVID-19
614 pandemic cases, hospitalisations, and deaths: a systematic review and meta-analysis. *J Glob*
615 *Health*. 2021;11:05015. <https://doi.org/10.7189/jogh.11.05015>
- 616 20. Hernandez I, Dickson S, Tang S, Gabriel N, Berenbrok LA, Guo J. Disparities in
617 distribution of COVID-19 vaccines across US counties: a geographic information system-

- 618 based cross-sectional study. PLoS Med. 2022;19(7):e1004069.
- 619 <https://doi.org/10.1371/journal.pmed.1004069>
- 620 21. Siegel M, Critchfield-Jain I, Boykin M, Owens A, Muratore R, Nunn T, et al. Racial/ethnic
621 disparities in state-level COVID-19 vaccination rates and their association with structural
622 racism. J Racial Ethn Health Disparities. 2022;9(6):2361-74.
- 623 <https://doi.org/10.1007/s40615-021-01173-7>
- 624 22. Centers for Disease Control and Prevention. COVID data tracker. CDC, 2022. Available
625 from: <https://covid.cdc.gov/covid-data-tracker/#vaccination-demographics-trends> [accessed
626 5 January 2023].
- 627 23. Underhill K, Johnson OCA. Vaccination equity by design. Yale Law J. 2021;131:53-88.
- 628 24. Victora CG, Joseph G, Silva ICM, Maia FS, Vaughan JP, et al. The inverse equity
629 hypothesis: analyses of institutional deliveries in 286 national surveys. Am J Public Health.
630 2018;108(4):464-71. <https://doi.org/10.2105/AJPH.2017.304277>
- 631 25. Khubchandani J, Macias Y. COVID-19 vaccination hesitancy in Hispanics and African-
632 Americans: a review and recommendations for practice. Brain Behav Immun Health.
633 2021;15:100277. <https://doi.org/10.1016/j.bbih.2021.100277>
- 634 26. Kricorian K, Turner K. COVID-19 vaccine acceptance and beliefs among Black and
635 Hispanic Americans. PLoS One. 2021;16(8):e0256122.
- 636 <https://doi.org/10.1371/journal.pone.0256122>
- 637 27. Mohottige D, Boulware LE. Trust in American medicine: a call to action for health care
638 professionals. Hastings Cent Rep. 2020;50(1):27-9. <https://doi.org/10.1002/hast.1081>

- 639 28. Benkert R, Cuevas A, Thompson HS, Dove-Meadows E, Knuckles D. Ubiquitous yet
640 unclear: a systematic review of medical mistrust. *Behav Med.* 2019;45(2):86-101.
641 <https://doi.org/10.1080/08964289.2019.1588220>
- 642 29. Jaiswal J, Halkitis PN. Towards a more inclusive and dynamic understanding of medical
643 mistrust informed by science. *Behav Med.* 2019;45(2):79-85.
644 <https://doi.org/10.1080/08964289.2019.1619511>
- 645 30. Williams DR, Mohammed SA. Racism and health I: pathways and scientific evidence. *Am*
646 *Behav Sci.* 2013;57(8):1152-73. <https://doi.org/10.1177/0002764213487340>
- 647 31. Schuster M, Eskola J, Duclos P; SAGE Working Group on Vaccine Hesitancy. Review of
648 vaccine hesitancy: Rationale, remit and methods. *Vaccine.* 2015;33(34):4157-60.
649 <https://doi.org/10.1016/j.vaccine.2015.04.035>
- 650 32. Larson HJ, Gakidou E, Murray CJL. The vaccine-hesitant moment. *N Engl J Med.*
651 2022;387(1):58-65. <https://doi.org/10.1056/nejmra2106441>
- 652 33. Dubé E, Laberge C, Guay M, Bramadat P, Roy R, Bettinger J. Vaccine hesitancy: an
653 overview. *Hum Vaccin Immunother.* 2013;9(8):1763-73. <https://doi.org/10.4161/hv.24657>
- 654 34. Bedford H, Attwell K, Danchin M, Marshall H, Corben P, Leask J. Vaccine hesitancy,
655 refusal and access barriers: the need for clarity in terminology. *Vaccine.* 2018;36(44):6556-
656 8. <https://doi.org/10.1016/j.vaccine.2017.08.004>
- 657 35. Colquhoun HL, Levac D, O'Brien KK, Straus S, Tricco AC, Perrier L, et al. Scoping
658 reviews: time for clarity in definition, methods, and reporting. *J Clin Epidemiol.*
659 2014;67(12):1291-4. <https://doi.org/10.1016/j.jclinepi.2014.03.013>

- 660 36. Newman PA, Reid L, Tepjan S, Fantus S, Allan K, Nyoni T, et al. COVID-19 vaccine
661 hesitancy among marginalized populations in the U.S. and Canada: protocol for a scoping
662 review. PLoS One. 2022;17(3):e0266120. <https://doi.org/10.1371/journal.pone.0266120>
- 663 37. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. Int J Soc
664 Res Methodol. 2005;8(1):19-32. <https://doi.org/10.1080/1364557032000119616>
- 665 38. Joanna Briggs Institute. Joanna Briggs institute reviewers' manual: 2015
666 edition/supplement. Adelaide: The Joanna Briggs Institute; 2015.
- 667 39. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA
668 Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern
669 Med. 2018;169(7):467-73. <https://doi.org/10.7326/m18-0850>
- 670 40. U.S. Department of Health & Human Services. Coronavirus: COVID-19 vaccines.
671 Washington: HHS, 2022 Dec 12. Available from: [https://www.hhs.gov/coronavirus/covid-](https://www.hhs.gov/coronavirus/covid-19-vaccines/index.html)
672 [19-vaccines/index.html](https://www.hhs.gov/coronavirus/covid-19-vaccines/index.html) [accessed 5 January 2023].
- 673 41. Health Canada. Health Canada authorizes first COVID-19 vaccine. Ottawa: Government of
674 Canada; 2020 Dec 9. Available from: [https://www.canada.ca/en/health-](https://www.canada.ca/en/health-canada/news/2020/12/health-canada-authorizes-first-covid-19-vaccine0.html)
675 [canada/news/2020/12/health-canada-authorizes-first-covid-19-vaccine0.html](https://www.canada.ca/en/health-canada/news/2020/12/health-canada-authorizes-first-covid-19-vaccine0.html) [accessed 5
676 January 2023].
- 677 42. Palmer Kelly E, McGee J, Obeng-Gyasi S, Herbert C, Azap R, Abbas A, et al.
678 Marginalized patient identities and the patient-physician relationship in the cancer care
679 context: a systematic scoping review. Support Care Cancer. 2021;29(12):7195-207.
680 <https://doi.org/10.1007/s00520-021-06382-8>
- 681 43. Landis JR, Koch GG. The measurement of observer agreement for categorical data.
682 Biometrics. 1977;33(1):159-74. <https://pubmed.ncbi.nlm.nih.gov/843571/>

- 683 44. Tricco AC, Antony J, Zarin W, Strifler L, Ghassemi M, Ivory J, et al. A scoping review of
684 rapid review methods. BMC Med. 2015;13:224. [https://doi.org/10.1186/s12916-015-0465-](https://doi.org/10.1186/s12916-015-0465-6)
685 [6](https://doi.org/10.1186/s12916-015-0465-6)
- 686 45. Garritty C, Gartlehner G, Nussbaumer-Streit B, King VJ, Hamel C, Kamel C, et al.
687 Cochrane Rapid Reviews Methods Group offers evidence-informed guidance to conduct
688 rapid reviews. J Clin Epidemiol. 2021;130:13-22.
689 <https://doi.org/10.1016/j.jclinepi.2020.10.007>
- 690 46. Allen JD, Abuelezam NN, Rose R, Fontenot HB. Factors associated with the intention to
691 obtain a COVID-19 vaccine among a racially/ethnically diverse sample of women in the
692 USA. Transl Behav Med. 2021;11(3):785-92. <https://doi.org/10.1093/tbm/ibab014>
- 693 47. Arvanitis M, Opsasnick L, O'Connor R, Curtis LM, Vuyyuru C, Yoshino Benavente J, et al.
694 Factors associated with COVID-19 vaccine trust and hesitancy among adults with chronic
695 conditions. Prev Med Rep. 2021;24:101484. <https://doi.org/10.1016/j.pmedr.2021.101484>
- 696 48. Balasuriya L, Santilli A, Morone J, Ainooson J, Roy B, Njoku A, et al. COVID-19 vaccine
697 acceptance and access among Black and Latinx communities. JAMA Netw Open.
698 2021;4(10):e2128575. <https://doi.org/10.1001/jamanetworkopen.2021.28575>
- 699 49. Battarbee AN, Stockwell MS, Varner M, Newes-Adeyi G, Daugherty M, Gyamfi-
700 Bannerman C, et al. Attitudes toward COVID-19 illness and COVID-19 vaccination among
701 pregnant women: a cross-sectional multicenter study during August-December 2020. Am J
702 Perinatol. 2022;39(01):075-083. <https://doi.org/10.1055/s-0041-1735878>
- 703 50. Bauer C, Zhang K, Lee M, Jones M, Rodriguez A, de la Cerda I, et al. Real-time geospatial
704 analysis identifies gaps in COVID-19 vaccination in a minority population. Sci Rep.
705 2021;11(1):18117. <https://doi.org/10.1038/s41598-021-97416-y>

- 706 51. Bogart LM, Ojikutu BO, Tyagi K, Klein DJ, Mutchler MG, Dong L, et al. COVID-19
707 related medical mistrust, health impacts, and potential vaccine hesitancy among Black
708 Americans living with HIV. *J Acquir Immune Defic Syndr*. 2021;86(2):200-7.
709 <https://doi.org/10.1097/qai.0000000000002570>
- 710 52. Bogart LM, Dong L, Gandhi P, Klein DJ, Smith TL, Ryan S, et al. COVID-19 vaccine
711 intentions and mistrust in a national sample of Black Americans. *J Natl Med Assoc*.
712 2022;113(6):599-611. <https://doi.org/10.1016/j.jnma.2021.05.011>
- 713 53. Carson SL, Casillas A, Castellon-Lopez Y, Mansfield LN, Morris D, Barron J, et al.
714 COVID-19 vaccine decision-making factors in racial and ethnic minority communities in
715 Los Angeles, California. *JAMA Netw Open*. 2021;4(9):e2127582.
716 <https://doi.org/10.1001/jamanetworkopen.2021.27582>
- 717 54. Chin ET, Leidner D, Ryckman T, Liu YE, Prince L, Alarid-Escudero F, et al. Covid-19
718 vaccine acceptance in California state prisons. *N Engl J Med*. 2021;385(4):374-6.
719 <https://doi.org/10.1056/NEJMc2105282>
- 720 55. Clark LR, Sawkin MT, Melton BL, Meyer EG. The COVID-19 vaccine conundrum: an
721 assessment of vaccine hesitancy amongst patients at a federally qualified health center. *J*
722 *Pharm Pract*. 2022:8971900221116193. <https://doi.org/10.1177/08971900221116193>
- 723 56. Crozier J, Christensen N, Li P, Stanley G, Clark DS, Selleck C. Rural, underserved, and
724 minority populations' perceptions of COVID-19 information, testing, and vaccination:
725 report from a southern state. *Popul Health Manag*. 2022;25(3):413-22.
726 <https://doi.org/10.1089/pop.2021.0216>

- 727 57. Ehde DM, Roberts MK, Herring TE, Alschuler KN. Willingness to obtain COVID-19
728 vaccination in adults with multiple sclerosis in the United States. *Mult Scler Relat Disord.*
729 2021;49:102788. <https://doi.org/10.1016/j.msard.2021.102788>
- 730 58. Ehde DM, Roberts MK, Humbert AT, Herring TE, Alschuler KN. COVID-19 vaccine
731 hesitancy in adults with multiple sclerosis in the United States: a follow up survey during
732 the initial vaccine rollout in 2021. *Mult Scler Relat Disord.* 2021;54:103163.
733 <https://doi.org/10.1016/j.msard.2021.103163>
- 734 59. Fernández-Penny FE, Jolkovsky EL, Shofer FS, Hemmert KC, Valiuddin H, Uspal JE, et
735 al. COVID-19 vaccine hesitancy among patients in two urban emergency departments.
736 *Acad Emerg Med.* 2021;28(10):1100-7. <https://doi.org/10.1111/acem.14376>
- 737 60. Fisher KA, Nguyen N, Crawford S, Fouayzi H, Singh S, Mazor KM. Preferences for
738 COVID-19 vaccination information and location: associations with vaccine hesitancy, race
739 and ethnicity. *Vaccine.* 2021;39(45):6591-4. <https://doi.org/10.1016/j.vaccine.2021.09.058>
- 740 61. Garcia J, Vargas N, de la Torre C, Magana Alvarez M, Clark JL. Engaging Latino families
741 about COVID-19 vaccines: a qualitative study conducted in Oregon, USA. *Health Educ*
742 *Behav.* 2021;48(6):747-57. <https://doi.org/10.1177/10901981211045937>
- 743 62. Garcia P, Montez-Rath ME, Moore H, Flotte J, Fults C, Block MS, et al. SARS-CoV-2
744 vaccine acceptability in patients on hemodialysis: a nationwide survey. *J Am Soc Nephrol.*
745 2021;32(7):1575–81. <https://doi.org/10.1681/asn.2021010104>
- 746 63. Geana MV, Anderson S, Ramaswamy M. COVID-19 vaccine hesitancy among women
747 leaving jails: a qualitative study. *Public Health Nurs.* 2021;38(5):892-6.
748 <https://doi.org/10.1111/phn.12922>

- 749 64. Ghaffari-Rafi A, Teehera KB, Higashihara TJ, Morden FTC, Goo C, Pang M, et al.
750 Variables associated with coronavirus disease 2019 vaccine hesitancy amongst patients
751 with neurological disorders. *Infect Dis Rep.* 2021;13(3):763-810.
752 <https://doi.org/10.3390/idr13030072>
- 753 65. Guidry JPD, Laestadius LI, Vraga EK, Miller CA, Perrin PB, Burton CW, et al.
754 Willingness to get the COVID-19 vaccine with and without emergency use authorization.
755 *Am J Infect Control.* 2021 Feb;49(2):137-42. <https://doi.org/10.1016/j.ajic.2020.11.018>
- 756 66. Hagan LM, Dusseau C, Crockett M, Rodriguez T, Long MJ. COVID-19 vaccination in the
757 Federal Bureau of Prisons, December 2020-April 2021. *Vaccine.* 2021;39(40):5883-90.
758 <https://doi.org/10.1016/j.vaccine.2021.08.045>
- 759 67. Iadarola S, Siegel JF, Gao Q, McGrath K, Bonuck KA. COVID-19 vaccine perceptions in
760 New York State's intellectual and developmental disabilities community. *Disabil Health J.*
761 2022;15(1):101178. <https://doi.org/10.1016/j.dhjo.2021.101178>
- 762 68. Jimenez ME, Rivera-Núñez Z, Crabtree BF, Hill D, Pellerano MB, Devance D, et al. Black
763 and Latinx community perspectives on COVID-19 mitigation behaviors, testing, and
764 vaccines. *JAMA Netw Open.* 2021;4(7):e2117074.
765 <https://doi.org/10.1001/jamanetworkopen.2021.17074>
- 766 69. Johnson KD, Akingbola O, Anderson J, Hart J, Chapple A, Woods C, Yeary K, McLean A.
767 Combatting a "Twin-demic": a quantitative assessment of COVID-19 and influenza
768 vaccine hesitancy in primary care patients. *Health Promot Perspect.* 2021;11(2):179-85.
769 <https://doi.org/10.34172/hpp.2021.22>
- 770 70. Jones DL, Salazar AS, Rodriguez VJ, Balise RR, Starita CU, Morgan K, et al. Severe acute
771 respiratory syndrome coronavirus 2: vaccine hesitancy among underrepresented racial and

- 772 ethnic groups with HIV in Miami, Florida. *Open Forum Infect Dis.* 2021;8(6):ofab154.
773 <https://doi.org/10.1093/ofid/ofab154>
- 774 71. Kuhn R, Henwood B, Lawton A, Kleva M, Murali K, King C, et al. COVID-19 vaccine
775 access and attitudes among people experiencing homelessness from pilot mobile phone
776 survey in Los Angeles, CA. *PLoS One.* 2021;16(7):e0255246.
777 <https://doi.org/10.1371/journal.pone.0255246>
- 778 72. Luo H, Qu H, Basu R, Rafferty AP, Patil SP, Cummings DM. Willingness to get a COVID-
779 19 vaccine and reasons for hesitancy among Medicare beneficiaries: results from a national
780 survey. *J Public Health Manag Pract.* 2022;28(1):70-6.
781 <https://doi.org/10.1097/phh.0000000000001394>
- 782 73. Masson CL, McCuistian C, Straus E, Elahi S, Chen M, Gruber VA, et al. COVID-19
783 vaccine trust among clients in a sample of California residential substance use treatment
784 programs. *Drug Alcohol Depend.* 2021;225:108812.
785 <https://doi.org/10.1016/j.drugalcdep.2021.108812>
- 786 74. Momplaisir F, Haynes N, Nkwihoreze H, Nelson M, Werner RM, Jemmott J.
787 Understanding drivers of coronavirus disease 2019 vaccine hesitancy among Blacks. *Clin*
788 *Infect Dis.* 2021;73(10):1784-9. <https://doi.org/10.1093/cid/ciab102>
- 789 75. Moore JX, Gilbert KL, Lively KL, Laurent C, Chawla R, Li C, et al. Correlates of COVID-
790 19 vaccine hesitancy among a community sample of African Americans living in the
791 southern United States. *Vaccines.* 2021;9(8):879. <https://doi.org/10.3390/vaccines9080879>
- 792 76. Myers A, Ipsen C, Lissau A. COVID-19 vaccination hesitancy among Americans with
793 disabilities aged 18-65: an exploratory analysis. *Disabil Health J.* 2022;15(1):101223.
794 <https://doi.org/10.1016/j.dhjo.2021.101223>

- 795 77. Okoro O, Kennedy J, Simmons G Jr, Vosen EC, Allen K, Singer D, et al. Exploring the
796 scope and dimensions of vaccine hesitancy and resistance to enhance COVID-19
797 vaccination in Black communities. *J Racial Ethn Health Disparities*. 2022;9(6):2117-30.
798 <https://doi.org/10.1007/s40615-021-01150-0>
- 799 78. Razzaghi H, Meghani M, Pingali C, Crane B, Naleway A, Weintraub E, et al. COVID-19
800 vaccination coverage among pregnant women during pregnancy - eight integrated health
801 care organizations, United States, December 14, 2020-May 8, 2021. *MMWR Morb Mortal*
802 *Wkly Rep*. 2021;70(24):895-9. <https://doi.org/10.15585/mmwr.mm7024e2>
- 803 79. Rodriguez RM, Torres JR, Chang AM, Haggins AN, Eucker SA, O'Laughlin KN, et al. The
804 rapid evaluation of COVID-19 vaccination in emergency departments for underserved
805 patients study. *Ann Emerg Med*. 2021;78(4):502-10.
806 <https://doi.org/10.1016/j.annemergmed.2021.05.026>
- 807 80. Rodriguez VJ, Alcaide ML, Salazar AS, Montgomerie EK, Maddalon MJ, Jones DL.
808 Psychometric properties of a vaccine hesitancy scale adapted for COVID-19 vaccination
809 among people with HIV. *AIDS Behav*. 2022;26(1):96-101. [https://doi.org/10.1007/s10461-](https://doi.org/10.1007/s10461-021-03350-5)
810 [021-03350-5](https://doi.org/10.1007/s10461-021-03350-5)
- 811 81. Rungkitwattanakul D, Yabusaki A, Singh D, Lawson P, Nwaogwugwu U, Iheagwara OS,
812 et al. COVID-19 vaccine hesitancy among African American hemodialysis patients: a
813 single-center experience. *Hemodial Int*. 2021;25(3):410-2.
814 <https://doi.org/10.1111/hdi.12922>
- 815 82. Salmon DA, Dudley MZ, Brewer J, Kan L, Gerber JE, Budigan H, et al. COVID-19
816 vaccination attitudes, values and intentions among United States adults prior to emergency

- 817 use authorization. *Vaccine*. 2021;39(19):2698-711.
- 818 <https://doi.org/10.1016/j.vaccine.2021.03.034>
- 819 83. Stephenson R, Sullivan SP, Pitter RA, Hunter AS, Chavanduka TM. COVID-19 pandemic
820 optimism and vaccine willingness among an online sample of US gay, bisexual, and other
821 men who have sex with men. *Vaccines*. 2021;9(7):745.
- 822 <https://doi.org/10.3390/vaccines9070745>
- 823 84. Stern MF, Piasecki AM, Strick LB, Rajeshwar P, Tyagi E, Dolovich S, et al. Willingness to
824 receive a COVID-19 vaccination among incarcerated or detained persons in correctional
825 and detention facilities - four states, September-December 2020. *MMWR Morb Mortal*
826 *Wkly Rep*. 2021;70(13):473-7. <https://doi.org/10.15585/mmwr.mm7013a3>
- 827 85. Stoler J, Enders AM, Kloststad CA, Uscinski JE. The limits of medical trust in mitigating
828 COVID-19 vaccine hesitancy among Black Americans. *J Gen Intern Med*.
829 2021;36(11):3629-31. <https://doi.org/10.1007/s11606-021-06743-3>
- 830 86. Teixeira da Silva D, Biello K, Lin WY, Valente PK, Mayer KH, Hightow-Weidman L, et
831 al. COVID-19 vaccine acceptance among an online sample of sexual and gender minority
832 men and transgender women. *Vaccines*. 2021;9(3):204.
- 833 <https://doi.org/10.3390/vaccines9030204>
- 834 87. Tsapepas D, Husain SA, King KL, Burgos Y, Cohen DJ, Mohan S. Perspectives on
835 COVID-19 vaccination among kidney and pancreas transplant recipients living in New
836 York City. *Am J Health Syst Pharm*. 2021;78(22):2040-5.
- 837 <https://doi.org/10.1093/ajhp/zxab272>
- 838 88. Uhr L, Mateen FJ. COVID-19 vaccine hesitancy in multiple sclerosis: a cross-sectional
839 survey. *Mult Scler*. 2022;28(7):1072-80. <https://doi.org/10.1177/13524585211030647>

- 840 89. Wagner AL, Sheinfeld Gorin S, Boulton ML, Glover BA, Morenoff JD. Effect of vaccine
841 effectiveness and safety on COVID-19 vaccine acceptance in Detroit, Michigan, July 2020.
842 Hum Vaccin Immunother. 2021;17(9):2940-5.
843 <https://doi.org/10.1080/21645515.2021.1917233>
- 844 90. Wang SX, Bell-Rogers N; FNP-c, Dillard D, Harrington MA. COVID-19 vaccine hesitancy
845 in Delaware's underserved communities. Dela J Public Health. 2021;7(4):168-75. doi:
846 10.32481/djph.2021.09.022
- 847 91. Xiang XM, Hollen C, Yang Q, Brumbach BH, Spain RI, Wooliscroft L. COVID-19
848 vaccination willingness among people with multiple sclerosis. Mult Scler J Exp Transl
849 Clin. 2021;7(2):20552173211017159. <https://doi.org/10.1177/20552173211017159>
- 850 92. Yang Y, Dobalian A, Ward KD. COVID-19 vaccine hesitancy and its determinants among
851 adults with a history of tobacco or marijuana use. J Community Health. 2021;46(6):1090-8.
852 <https://doi.org/10.1007/s10900-021-00993-2>.
- 853 93. Zhang M, Gurung A, Anglewicz P, Subedi P, Payton C, Ali A, et al. Acceptance of
854 COVID-19 vaccine among refugees in the United States. Public Health Rep.
855 2021;136(6):774-81. <https://doi.org/10.1177/00333549211045838>
- 856 94. Ramsetty A, Adams C. Impact of the digital divide in the age of COVID-19. J Am Med
857 Informatics Assoc. 2020;22(7):1147-8. <https://doi.org/10.1093/jamia/ocaa078>
- 858 95. Ratzan S, Schneider EC, Hatch H, Cacchione J. Missing the point - how primary care can
859 overcome Covid-19 vaccine "hesitancy". N Engl J Med. 2021;384(25):e100.
860 <https://doi.org/10.1056/nejmp2106137>

- 861 96. Dada D, Djiometio JN, McFadden SM, Demeke J, Vlahov D, Wilton L, et al. Strategies
862 that promote equity in COVID-19 vaccine uptake for Black communities: a review. J
863 Urban Health. 2022;99(1):15-27. <https://doi.org/10.1007/s11524-021-00594-3>
- 864 97. Rodriguez RM, Nichol G, Eucker SA, Chang AM, O'Laughlin KN, Pauley A, et al. Effect
865 of COVID-19 vaccine messaging platforms in emergency departments on vaccine
866 acceptance and uptake: a cluster randomized clinical trial. JAMA Intern Med. 2022.
867 <https://doi.org/10.1001/jamainternmed.2022.5909>
- 868 98. Peretti-Watel P, Larson HJ, Ward JK, Schulz WS, Verger P. Vaccine hesitancy: clarifying
869 a theoretical framework for an ambiguous notion. PLoS Curr.
870 2015;7:ecurrents.outbreaks.6844c80ff9f5b273f34c91f71b7fc289.
871 <https://doi.org/10.1371/currents.outbreaks.6844c80ff9f5b273f34c91f71b7fc289>
- 872 99. Sturgis P, Brunton-Smith I, Jackson J. Trust in science, social consensus and vaccine
873 confidence. Nat Hum Behav. 2021;5(11):1528-34. [https://doi.org/10.1038/s41562-021-](https://doi.org/10.1038/s41562-021-01115-7)
874 [01115-7](https://doi.org/10.1038/s41562-021-01115-7)
- 875 100. Rubincam C, Lacombe-Duncan A, Newman PA. Taking culture seriously in biomedical
876 HIV prevention trials: a meta-synthesis of qualitative studies. Expert Rev Vaccines.
877 2015;15(3):331-47. <https://doi.org/10.1586/14760584.2016.1118349>
- 878 101. Demeke J, Ramos SR, McFadden SM, Dada D, Nguemo Djiometio J, Vlahov D, et al.
879 Strategies that promote equity in COVID-19 vaccine uptake for Latinx communities: a
880 review. J Racial Ethn Health Disparities. 2022:1-9. [https://doi.org/10.1007/s40615-022-](https://doi.org/10.1007/s40615-022-01320-8)
881 [01320-8](https://doi.org/10.1007/s40615-022-01320-8)
- 882 102. U.S. Department of Health and Human Services. Campaign approach to reaching Black
883 audiences. Washington: HHS, 2022 Sep 19. Available from:

884 <https://wecandohis.hhs.gov/resource/campaign-approach-to-reaching-black-audiences>

885 [accessed 5 January 2023].

886 103. Centers for Disease Control and Prevention. Guidance for vaccinating older adults and
887 people with disabilities: ensuring equitable COVID-19 vaccine access. Atlanta: CDC, 2022
888 Jan 20. Available from: [https://www.cdc.gov/vaccines/covid-19/clinical-
889 considerations/older-adults-and-disability/access.html](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/older-adults-and-disability/access.html) [accessed 5 January 2023].

890

891 **Supporting information**

892 **S1 Table. Sample search string**

medRxiv preprint doi: <https://doi.org/10.1101/2023.02.23.23286342>; this version posted February 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).





Figure 1



medRxiv preprint doi: <https://doi.org/10.1101/2023.02.23.23286342>; this version posted February 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).